Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
EC

NASDAQ · ECOR

electroCore, Inc.

Healthcare · Medical - Devices

$7.52

Down-$0.59 (-7.27%)

Updated Nov 1, 2026, 10:50 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.09M
P/E ratio
-3.07
Dividend yield
0.00%
52-week range
$4.41 – $12.70
Volume
65.78K
Avg. volume
53.04K

Price performance · ECOR

ECOR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ECOR closed at $7.52 after 20 trading sessions, down 25.77% for the selected period.

Last close
$7.52
Period change
-25.77%
Period low
$7.05
Period high
$10.13
Daily close
View OHLC price history
ECOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$7.76$8.54$7.495$7.5265.78K
Oct 29, 2026$8.47$8.56$8.11$8.1133.03K
Oct 28, 2026$7.76$8.56$7.65$8.4245.04K
Oct 27, 2026$7.58$7.90$7.47$7.7662.14K
Oct 26, 2026$7.07$7.57$7.07$7.4471.32K
Oct 23, 2026$7.25$7.50$7.00$7.05131.2K
Oct 22, 2026$7.13$7.7199$7.13$7.4138.07K
Oct 21, 2026$7.9473$7.9473$7.27$7.3553.14K
Oct 20, 2026$7.52$8.00$7.40$7.4955.21K
Oct 19, 2026$7.82$8.1755$7.40$7.6370.69K
Oct 16, 2026$8.29$8.42$7.35$7.85141.38K
Oct 15, 2026$8.13$8.4985$7.87$8.3593.42K
Oct 14, 2026$8.26$8.57$8.02$8.20118.72K
Oct 13, 2026$9.12$9.3877$8.15$8.39184.74K
Oct 12, 2026$9.78$9.78$8.97$9.2855.29K
Oct 9, 2026$9.37$9.79$9.37$9.6644.57K
Oct 8, 2026$9.65$10.0499$9.42$9.5152.89K
Oct 7, 2026$9.8201$10.2299$9.685$9.7248.63K
Oct 6, 2026$10.25$10.4499$9.89$9.9239.72K
Oct 5, 2026$10.14$10.2499$9.90$10.1331.99K

Latest ECOR news

The latest Smart Investors Daily articles mentioning ECOR.

Stock researchCompany · Overview

ECOR research

Overview

Company profile and research snapshot.

Company profile

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ECOR recent ratings
DateFirmRatingTarget
Jan 26, 2026HC Wainwright & Co.Buy—
Mar 13, 2025Ladenburg ThalmannBuy—
Mar 13, 2025HC Wainwright & Co.Buy—
Dec 18, 2024HC Wainwright & Co.Buy—
Mar 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

Generated Oct 31, 2026, 9:21 PM

Why Is ECOR Down Today?

electroCore shares declined 7.27% today despite the company announcing its Q3 2026 earnings report scheduled for November 4, 2026. The sell-off appears driven by broader market sentiment rather than company-specific negative news, as the only recent headline is a routine earnings announcement notification.

    Bottom line: electroCore's 7.27% decline appears to be a pre-earnings pullback rather than a response to negative company news, with the Q3 2026 earnings announcement scheduled for November 4 serving as the next major catalyst. Investors should focus on whether the company demonstrates revenue growth, market expansion, or positive clinical developments when results are announced, as the current lack of headline-generating news may indicate competitive or execution challenges.

    Yahoo · Oct 29, 2026

    electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

    ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions. Participants may join by telephone or webcast using the details below.

    Yahoo · Oct 28, 2026

    electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

    Submission backed by clinical data from two clinical studies representing 168 subjects demonstrating quality of life improvements and an approximately 40% reduction in neuropathic pain scores in the active treatment groupROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), (“electroCore” or the “Company”), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By